Randomized Active and Placebo-Controlled Endoscopy Study of a Novel Protected Formulation of Oral Alendronate
- 27 April 2006
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 51 (5) , 864-868
Abstract
Although generally well tolerated, oral aminobisphosphonates have been associated with sporadic cases of severe esophageal injury attributed to pill contact. A novel protected formulation of oral alendronate uses an inert cylindrical shell to prevent mucosal contact with intact tablets. An active and placebo-controlled endoscopy study was undertaken to assess mucosal injury associated with this protected formulation. Healthy volunteers with normal baseline endoscopy were randomly assigned to receive protected alendronate 70 mg/day, standard alendronate 70 mg/day, or placebo for 14 days. Endoscopy was repeated on days 8 and 15. Of 78 subjects, 30 received protected alendronate, 28 received standard alendronate, and 20 received placebo. Mean gastric injury scores did not differ significantly among treatment groups. However, subjects on standard alendronate were more likely than those on protected alendronate to develop severe gastric injury, defined as Lanza score 3 or 4 (67.9% versus 33.3%, P=.009), and more likely to develop a gastric ulcer (21.4% versus 3.3%, P=.015). No differences in symptoms or adverse events were observed. In conclusion, a novel protected formulation of oral alendronate is less likely than standard alendronate to induce severe mucosal injury to the upper gastrointestinal tract.Keywords
This publication has 9 references indexed in Scilit:
- 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.2002
- The gastrointestinal tolerability and safety of oral bisphosphonatesExpert Opinion on Drug Safety, 2002
- Fatal esophageal perforation with alendronateAmerican Journal of Gastroenterology, 2001
- Placebo‐controlled, randomized, evaluator‐blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal womenAlimentary Pharmacology & Therapeutics, 2000
- A randomized controlled trial to assess alendronate‐associated injury of the upper gastrointestinal tractAlimentary Pharmacology & Therapeutics, 2000
- Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal womenGastroenterology, 2000
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996
- Healing and relapse of severe peptic esophagitis after treatment with omeprazoleGastroenterology, 1988
- ETODOLAC COMPARED WITH ASPIRIN - AN ENDOSCOPIC STUDY OF THE GASTROINTESTINAL TRACTS OF NORMAL VOLUNTEERS1986